Odyssey Health FY 2026: Net loss $5.73M, Diluted EPS ($0.05) — 10-K Summary
Odyssey Health reported a net loss of $5.73M for fiscal 2026, widening from a $1.74M loss in 2025. Diluted loss per share was $0.05, up from $0.02. The company is developing CardioMap and Save-A-Life devices, neither cleared for sale. Future plans depend on securing funding.
How this was made
The 30-second read
Why it matters
The 10‑K loss widening suggests higher operating expenses and possible cash‑flow strain, which could trigger share sell‑offs unless new capital is raised.
Market read
Micro‑cap investors will watch for financing updates; broader market impact is limited.
What to watch
Potential upcoming regulatory clearances or partnership announcements could offset the loss impact.
Background
Odyssey Health is a small medical‑device company developing heart‑monitoring and choking‑rescue technologies that are not yet commercialized.
Ticker impact
Odyssey Health filed its 10‑K reporting a widened FY 2026 net loss of $5.73 M versus $1.74 M a year earlier.
likely downward pressure as investors price in the larger loss and funding uncertainty
Micro‑cap earnings surprises typically move the share price; a 228% loss increase raises concerns about liquidity.
Market effects
Highlights ongoing funding challenges for early‑stage medical‑device firms.
Limited to U.S. micro‑cap investors; no broader regional effect.
Minimal global relevance beyond niche biotech/medical‑device space.
Counterpoint
If the company secures new financing, the loss may be viewed as a temporary setback, offering a buying opportunity at depressed prices.
Key entities
- companyOdyssey Health, Inc.
Developer of CardioMap heart‑monitoring and Save‑A‑Life choking rescue device.
